Catalyst ligands

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The phase-transfer catalysts (C1-C11) were synthesized according to the proceduresbelow. To a solution of cinchonidine (1.00 g, 3.4 mmol) in THF (50 mL) was addedthe aryl benzyl bromides (3.4 mmol). The mixture was heated for 6-8 h at reflux.After cooling to room temperature, the mixture was poured into MTBE (150 mL)under stirring. The precipitated solid was filtrated and recrystallized fromCH3OH/MTBE to afford C1-C11

485-71-2, 485-71-2 Cinchonidine 101744, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Li, Ruipeng; Liu, Zhenren; Chen, Liang; Pan, Jing; Zhou, Weicheng; Beilstein Journal of Organic Chemistry; vol. 14; (2018); p. 1421 – 1427;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

500 mg of compound 19-3 and 1.3 g of compound 17-1 were dissolved in 20 mL of acetonitrile, and 680 mg of potassium carbonate was added thereto, and the mixture was heated to reflux overnight, cooled to room temperature, filtered, and the filtrate was concentrated and evaporated. Column chromatography (PE: EA = 20: 1-1: 1) to give a colorless waxy compound 19-4 510mg, Yield: 40.4%.

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Shenzhen Xiaxiwan Pharmaceutical Technology Co., Ltd.; Qi Fei; Xia Junxia; Zhang Zaijun; Wang Liang; (27 pag.)CN109988153; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: To a solution of 2-phenyl-3-hydroxy-4(1H)-quinolinone (237 mg, 1 mmol) in ethanol (50 mL), the corresponding bidentate N-donor ligand (L) (1 mmol) dispersed in EtOH (5 mL) was added while stirring. To this mixture, a solution of Cu(BF4)2¡¤H2O (237 mg, 1 mmol) in H2O (5 mL) was slowly added while stirring. The reaction mixture was stirred at room temperature for a few hours, and subsequently left to stand for several days at room temperature. The obtained solid product was filtered off, washed with a small amount of cold water and ethanol, and dried in the air at 40 C., 1662-01-7

The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Buchtik, Roman; Travnicek, Zdenek; Vanco, Jan; Journal of Inorganic Biochemistry; vol. 116; (2012); p. 163 – 171;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Pt2Me4(mu-SMe2)2] (51mg, 0.09mmol) in acetone (5mL) was added a solution of bphen (59mg, 0.18mmol) in acetone (30mL). The reaction color changed to deep red and the solution stirred for 2h at room temperature. After removal of the solvent under reduced pressure, the dark red complex was obtained and air dried. Yield: 72%; m.p. 221C (dec). Anal. Calc. for C26H22N2Pt: C, 56.01; H, 3.98; N, 5.02. Found: C, 55.67; H, 4.27; N, 4.77%. NMR data in CDCl3: delta(1H) 1.30 [s, 6H, 2J(Pt-H)=85.3Hz, Pt-Me], 7.56 [s, 10H, Ph groups], 7.75 [d, 2H, 3J(HH)=5.1Hz, H3], 7.94 [s, 2H, H5], 9.56 [d, 2H, 3J(HH)=5.1Hz, 3J(Pt-H)=25.4Hz, H2]; delta(13C)-17.1 [s, 1J(Pt-C)=804Hz, Pt-Me], 125.2 (C5), 126.1 [C3, 2J(Pt-C)=19Hz], 128.8 (C1), 129.2-129.4 (Ph groups), 137.1 (C13), 146.4 [C2, 2J(Pt-C)=33Hz], 148.6 (C11), 148.8 (C4); delta(195Pt)-3359. UV-Vis (lambdamax in toluene): 474 and 516nm.

1662-01-7, As the paragraph descriping shows that 1662-01-7 is playing an increasingly important role.

Reference£º
Article; Momeni, Badri Z.; Fathi, Nastaran; Moghadasi, Milad; Biglari, Abbas; Janczak, Jan; Journal of Organometallic Chemistry; vol. 880; (2019); p. 368 – 377;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

13910-48-0, N1-Benzylpropane-1,3-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Pyrazolone 1b (643 mg, 1.88 mmol) was dissolved in CH3CN (10 mL) and amine 2N-benzylpropane-1,3-diamine was added at 0 C under N2. The reaction mixture was stirred at 0 C for 3 h and monitored by LC-MS showing 40% of starting material left. Then DIPEA (two drops) was added and the mixture was stirred at RT for 1 h: LC-MS showed completely conversion of starting material into desired product. The solvent was concentrated in vacuo until dryness. The residue was dissolved in ethylacetate (10 mL), washed with saturated NaHCO3 solution (5 mL * 2), dried over Na2SO4 and concentrated. The crude product was used in the following step without further manipulation (530 mg, 71% yield, 86% HPLC purity, LC-MS (M+H)+: 453.4).

13910-48-0, 13910-48-0 N1-Benzylpropane-1,3-diamine 83811, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Gaggini, Francesca; Laleu, Benoit; Orchard, Mike; Fioraso-Cartier, Laetitia; Cagnon, Laurne; Houngninou-Molango, Sophie; Gradia, Angelo; Duboux, Guillaume; Merlot, Cedric; Heitz, Freddy; Szyndralewiez, Cedric; Page, Patrick; Bioorganic and Medicinal Chemistry; vol. 19; 23; (2011); p. 6989 – 6999;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.294-90-6,1,4,7,10-Tetraazacyclododecane,as a common compound, the synthetic route is as follows.

Di-tert-butyl dicarbonate (16.5 g, 0.076 mol) in chloroform (100 mL) was added dropwise to a chilled mixture of 1 ,4,7,10-tetraazacyclododecane (5.0 g, 0.029 mol) and diisopropylamine (15 mL, 0.087 mol) in chloroform (200 mL) over a period of three hours. The reaction was then stirred overnight under an atmosphere of nitrogen. The reaction was concentrated, brought up in ethyl acetate (600 mL) and washed with saturated sodium bicarbonate (200 mL), followed by one wash of monobasic potassium phosphate (200 mL of 1 M) and brine (200 mL). The ethyl acetate was dried over sodium sulfate, filtered and concentrated. The crude reaction was purified using flash chromatography (4:1 ethyl acetate :hexanes) to yield a white solid (7.84 g, 57%). 1H NMR (400 MHz, CDCI3) delta 3.67-3.52 (br, 4H), 3.46-3.14 (m, 8H), 2.88-2.72 (br, 4H), 1 .44 (s, 9H), 1 .42 (s, 18H); 13C NMR (100 MHz, CDCI3) delta 155.4, 79.2, 79.1 , 50.8, 49.3, 49.3, 48.7, 45.8, 44.8, 28.5, 28.3; LRMS (ESI): m/z [M+H]+ calc’d for C23H45N406+ 473.33, found 473.33., 294-90-6

The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; GUNNING, Patrick Thomas; DA SILVA, Sara R.; PAIVA, Stacey-Lynn; LUKKARILA, Julie Lynn; WO2015/179955; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.,4568-71-2

(1) Preparation of methyl 4-(2-furyl)-4-oxobutyrate (Compound 26F-A) After 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (1.0 g, 4 mmols) and triethylamine (2.02 g, 20 mmols) were added to a solution of furfural (4.8 g, 50 mmols) in absolute ethanol (30 ml). The mixture was stirred at room temperature for 40 minutes. Methyl acrylate (5.0 g, 50 mmols) was further added to the mixture followed by heating to reflux for 7 hours. The reaction solution was concentrated in vacuo. The residue obtained was purified by silica gel column chromatography (600 ml, hexane:ethyl acetate=2:1) to give Compound (26F-A) (3430 mg, yield: 37.6percent). 1H-NMR (200 MHz, CDCl3) delta: 2.74 (2H, t, J=6.8 Hz), 3.18 (2H, t, J=6.8 Hz), 6.54 (1H, dd, J=1.7 Hz, 3.6 Hz), 7.23 (1H, dd, J=0.7 Hz, 3.6 Hz), 7.59 (1H, dd, J=0.7 Hz, 1.7 Hz); MS (FAB, POS) m/z: 180 (M+H)+.

The synthetic route of 4568-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Nippon Kayaku Kabushiki Kaisha; US6384063; (2002); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

99970-84-0, [2,2′-Bipyridine]-4,4′-dicarbaldehyde is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

99970-84-0, 6-(2′-aminoethyl)-3,6,9-triaza-1(2,6)-pyridinacyclodecaphane (443.2 mg, 1.78 mmol) and 2,2′-bipyridine-4,4′-dicarbaldehyde(198 mg, 0.93 mmol) were dissolved in 40 mL of anhydrous ethanol and the mixture was stirred for 2 h at room temperature. NaBH4(550 mg, 14.5 mmol) was then added and the resulting solution stirred for 2 h at room temperature. The ethanol was removed under reduced pressure. The resulting residue was treated with H2O (10 mL) and extracted with CH2Cl2 (3 ¡Á 20mL). The organic phase was removed at reduced pressure, and the resulting residue was dissolved in ethanol and precipitated as the hydrochloride salt of L3 in 75% yield. mp: N 345 C. 1H NMR (300MHz, D2O): deltaH (ppm)=8.88 (d, J=5.5 Hz, 2H), 8.55 (s, 2H),7.94 (d, J=5.5 Hz, 2H), 7.92 (t, J=8 Hz, 2H), 7.42 (d, J=8 Hz, 4H), 4.60(s, 4H), 4.59 (s, 8H), 3.47 (t, J=8Hz, 4H), 3.26(t, J=5.3Hz, 8H), 3.13 (t,J = 8 Hz, 4H), 2.92 (t, J = 5.3 Hz, 8H). 13C NMR (75.43 MHz, D2O): deltaC(ppm) = 149.4, 148.9, 147.7, 146.1, 139.8, 127.0, 124.3, 122.2, 50.8,50.5, 50.0, 49.5, 45.9, 43.9. Calc for C38H54N12*8HCl*9H2O: C 40.3%, H7.1%,N 14.8%. Found: C 40.4%, H 7.3%, N 14.9%. MS (FAB)m/z 680 [MH]+.

99970-84-0 [2,2′-Bipyridine]-4,4′-dicarbaldehyde 4171663, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Gonzalez-Garcia, Jorge; Martinez-Camarena, Alvar; Verdejo, Begona; Clares, M. Paz; Soriano, Concepcion; Garcia-Espana, Enrique; Jimenez, Hermas R.; Domenech-Carbo, Antonio; Tejero, Roberto; Calvo, Enrique; Brianso-Llort, Laura; Serena, Carolina; Trefler, Sandra; Garcia-Espana, Antonio; Journal of Inorganic Biochemistry; vol. 163; (2016); p. 230 – 239;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

114527-28-5, 4-(4′-Methyl-[2,2′-bipyridin]-4-yl)butanoic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Synthesis of a weak light frequency upconversion triplet sensitizer4 – methyl – 4 – butyric acid – 2,2 – bipyridine and ruthenium trichloride were added to ethylene glycol ether solvent, and the reaction was heated at refluxAfter 12 hours, the solvent was removed and recrystallization was carried out to give tris (4-methyl-4-butyldicarboxylic acid 2,2-bipyridyl)ruthenium complex.

114527-28-5, As the paragraph descriping shows that 114527-28-5 is playing an increasingly important role.

Reference£º
Patent; Suzhou University of Science and Technology; Zhou, Yuyang; Ma, Haonan; Wang, Xiaomei; Ye, Changqing; (15 pag.)CN105601560; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

COMPOUKD 29; 5J0-bis-[4-(3-Trimethylammonio-propyloxy)-phenyl]-15,20-bis-(4- undecyloxy-phenyl)-porphyrin dichloride; Compound 14 (50 mg, 0.05 mmol) is dissolved and K2CO3 (150 mg, 1.1 mmol) is suspended in DMF (30 mL). To the vigorously- stirred mixture a solution of (l-bromopropyl)-trimethylammonium bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 500C and the mixture is heated for 18 h. After removal of DMF under high vacuum, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid:methanol:water (3 :2:1, by vol.). After evaporation of solvent from appropriate combined fractions the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (5:4: 1, by vol.. upper phase) for further separation from the excess ammonium salt and other by-products. After removal of solvent under reduced pressure the residue obtained is dissolved in methanol and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After evaporation of solvent under reduced pressure, the product is dried under high vacuum.1H-NMR: deltaH (300MHz, CD3OD): 0.80 (t, 3J 7.5 Hz, 6 H), 1.15-1.35 (m, 28 H), 1.35-1.45 (bs, 4 H), 1.70-1.80 (bs, 4 H), 2.30-2.40 (bs, 4 H), 3.15-3.30 (bs, 18 H), 3.65-3.75 (bs5 4 H), 4.00-4.05 (m, 4 H), 4.30-4.40 (bs, 4 H), 7.00-7.15, 7.20-7.30, 7.80-95, 7.95-8.15 (4 x m, 4 x 4 H), 8.60-9.00 (bs, 8 H).

3779-42-8, As the paragraph descriping shows that 3779-42-8 is playing an increasingly important role.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI